linjc16/ctgov huggingface dataset:
Lung Cancer Diagnosis and Staging Using Ultrasound Guidance

Study Overview
=================
Brief Summary
-----------------
To collect data of all patients who have undergone Endobronchial ultrasound for diagnosis or staging of suspected lung cancer

Detailed Description
-----------------
Introduction: Endobronchial Ultrasound (EBUS) is a procedure that is performed via flexible bronchoscopy under moderate sedation for visualization of lymph nodes in the chest and biopsy under real-time guidance for the staging of lung cancer or evaluation of enlarged lymph nodes. In addition, lung lesions or masses can be visualized and biopsied in the same sitting. The use of EBUS has enhanced the safety and diagnostic yield of flexible bronchoscopy. Aim: The data of patients with suspected lung cancer or undiagnosed lymph node enlargement in whom bronchoscopy with EBUS guidance is clinically indicated will be collected prospectively. Results from EBUS are considered positive if a specific diagnosis is obtained ( eg malignancy) or if lymphocytes are present in the lymph node biopsy, indicating accurate sampling of lymph node. In patients with non-diagnostic EBUS, the results from other procedures will be compared for analysis.

Official Title
-----------------
Diagnosis and Staging of Lung Cancer Using Minimally Invasive Technique With Ultrasound Guidance

Conditions
-----------------
Lung Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who have undergone endobronchial ultrasound Exclusion Criteria: None

Ages Eligible for Study
-----------------
Minimum Age: 21 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Endobronchial ultrasound, lung cancer
Integrating Pediatric Pharmacogenomic Testing Into the Canadian Health Care System

Study Overview
=================
Brief Summary
-----------------
This project addresses the problem of adverse drug reactions in the three most frequently prescribed therapeutic classes of drugs in children: antibiotics, analgesics, and mental health medications. We will conduct pilot testing of a pharmacogenomic testing panel and study how the tests and generated test results are utilized and understood by physicians, pharmacists, patients and their families.

Detailed Description
-----------------
The specific objectives are to: Implement a pilot pharmacogenomics program to test medication safety and effectiveness of antibiotics, analgesics and mental health medication to enhance prescribing decision-making. Develop data collection forms to collect necessary patient information from the prescribing physicians. Develop pharmacogenomics reports to return results to physicians, pharmacists, patients and their families. Determine how the tests and results are perceived and utilized by physicians, pharmacists, patients and their families.

Official Title
-----------------
Integrating Pediatric Pharmacogenomic Testing Into the Canadian Health Care System

Conditions
-----------------
Adverse Drug Reaction (ADR)

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Participants will be enrolled if they can benefit from pharmacogenomic testing. This means their physician is considering the use of a drug that is part of the panels (analgesics, antibiotics, and mental health medication) or they are already using one. Exclusion Criteria: Patients who do not speak or understand English.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 150 participants on analgesics, anti-infectives and psychotropics will be given pharmacogenomic recommendations for the risk of gene related adverse events prior to or during treatment. | We will be able to determine the barriers and facilitators of the implementation of the pharmacogenomic service in a health care facility. This will be done by using standardized questionnaires after each pharmacogenomic report is issued. The prescriber and the patient will both answer questions about the utility of the genetic results, the format of the report and the clarity of the content. Results will be recorded and summarized every 25 patients in order to improve the service and the recommendations through the study. | June 2020 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Pharmacogenomics, Pediatrics, Adverse Drug Reactions
Study of Biomarkers in Tissue Samples From Patients With Metastatic Colon Cancer

Study Overview
=================
Brief Summary
-----------------
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer. PURPOSE: This research study is looking at biomarkers in tissue samples from patients with metastatic colon cancer.

Detailed Description
-----------------
OBJECTIVES: Determine the effect of surgical resection, in terms of physiological stress, on levels of tumor markers such as protein kinase A (PKA) expression in patients with metastatic colon cancer. Estimate variation among patients of baseline tumor markers in tumor tissue and sera. Correlate markers in tumor tissues with that in sera in these patients. Establish a tissue bank of these specimens for future studies. OUTLINE: Biopsy and surgical specimens are obtained before and during standard surgery (patients may have had tumor tissue obtained before study entry and stored). Serum samples and tumor tissue are analyzed by immunohistochemistry and western blot. Tumor markers (such as PKA expression) are determined and marker levels are measured in serum samples and tissues. PROJECTED ACCRUAL: Approximately 30 patients will be accrued for this study.

Official Title
-----------------
Assessment of Variation of PKA and Other Molecular Markers in Patients Undergoing Resection of Colon Cancer Metastases

Conditions
-----------------
Colorectal Cancer

Intervention / Treatment
-----------------
* Genetic: western blotting
* Other: immunohistochemistry staining method
* Other: laboratory biomarker analysis


Participation Criteria
=================
Eligibility Criteria
-----------------
DISEASE CHARACTERISTICS: Diagnosis of colon cancer Metastatic disease for which surgical resection is indicated Metastatic disease accessible for tissue biopsy OR previously biopsied tissue is available PATIENT CHARACTERISTICS: Platelet count ≥ 80,000/mm^3 INR ≤ 1.3 PTT ≤ upper limit of normal No history of bleeding disorders or abnormal clotting factors No extrahepatic biliary obstruction PRIOR CONCURRENT THERAPY: See Disease Characteristics

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Genetic: western blotting|nan|
|Other: immunohistochemistry staining method|nan|
|Other: laboratory biomarker analysis|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
stage IV colon cancer, recurrent colon cancer
Females With Severe or Moderate Hemophilia A or B: an International Multi-center Study

Study Overview
=================
Brief Summary
-----------------
This is a multi-center, international study designed to collect clinical, genetic and quality of life information on females with hemophilia, an inherited bleeding disorder. The study is designed to determine whether there are problems and issues unique to females with hemophilia.

Detailed Description
-----------------
The study involves two questionnaires: one on the diagnosis, symptoms, complications and treatment of each participant to be completed by a staff member; the other is a questionnaire to be completed by the participant on how the disease has affected her life. Finally, for those participants who have not previously had genetic testing, the third part of the study is an optional blood test to determine the genetic cause, what change in the factor VIII or factor IX gene, caused the hemophilia. The test results will be available to those participants who wish to learn their results. With the data we collect we will compile a database to examine the connection between the genetic cause of hemophilia and the course and symptoms of the disease.

Official Title
-----------------
Females With Severe or Moderate Hemophilia A or B: an International Multi-center Study

Conditions
-----------------
Hemophilia A, Hemophilia B

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Females with severe (FVIII<0.01u/ml) or moderate (FVIII 0.01≤0.05 u/ml) hemophilia A Females with severe (FIX<0.01u/ml) or moderate (FIX 0.01≤0.05u/ml) hemophilia B Willingness to participate in the study. Exclusion Criteria: Subjects who do not meet the inclusion criteria with respect to gender or hemophilia severity.
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Females with Hemophilia<br>Females with severe or moderate Hemophilia A or B | |
| Control group<br>Male subjects with severe Hemophilia A or B and female subjects with mild (20-60%) Hemophilia A or B. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The molecular and cytogenetic etiology of the condition will be compiled. Clinical manifestation demonstrated by the female hemophiliacs will be compared to published data available. Genotype and phenotype will be correlated. |  | 1-2 visits |
Safety And Efficacy Study Of CP-675,206 In HIV-Infected Patients

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine if CP-675,206, a monoclonal antibody to CTLA4, is safe and well-tolerated, reduces viral load, and improves immune function in patients infected with HIV.

Official Title
-----------------
A Phase 2 Study To Evaluate The Safety, Tolerability, Virologic And Immunologic Effect Of Single-Dose CP-675,206 In Patients Infected With Human Immunodeficiency Virus

Conditions
-----------------
Human Immunodeficiency Virus

Intervention / Treatment
-----------------
* Drug: CP-675,206


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: HIV infected man or woman at least 18 years of age who is available for a follow up period of at least 3 months Has been on a stable antiretroviral regimen for ≥3 months and willing to remain on current antiretroviral regimen for an additional 3 months or has been off of antiretroviral therapy for at least 8 weeks and willing to remain off of antiretroviral therapy for another 3 months Plasma HIV 1 RNA ≥5,000 copies/mL measured by Roche Amplicor HIV 1 Monitor at the screening visit CD4 T-cells ≥200 cells/mm3 Exclusion Criteria: History of, or significant evidence of risk for, chronic inflammatory or autoimmunedisease (eg, Addison's disease, asthma, celiac disease, multiple sclerosis, Graves disease, Hashimoto's thyroiditis, inflammatory bowel disease, psoriasis, rheumatoid arthritis, systemic lupus erythematosus, etc) History of inflammatory bowel disease (eg, Crohn's disease or ulcerative colitis), celiac disease, or other chronic gastrointestinal conditions associated with diarrhea, or current acute colitis of any origin, and any history of diverticulitis (even a single episode) or evidence of diverticulitis at baseline, including evidence limited to CT-scan only Exposure within the previous 3 months to a drug known to have immunomodulatory effects (eg, IL 2)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Single


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: CP-675,206|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Maximum reduction in HIV plasma RNA between Baseline and Week 12 Maximum increase in CD4+ cell count between Baseline and Week 12 |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from baseline in CD8+ cell count, CD4/CD8, and lymphocyte phenotype through Week 12 |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
HIV Therapeutic Vaccine
Neural Bases of Multiple Forms of Self-regulatory Control in Bulimia Nervosa

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to investigate areas of the brain responsible for self-regulation in adult women who have never had an eating disorder with women who have bulimia nervosa. More specifically, investigators are interested in changes in brain activation (e.g., changes in blood flow and oxygen use) when inhibiting responses and regulating emotions. Data collection will rely on a technology called functional magnetic resonance imaging (fMRI).

Official Title
-----------------
Neural Bases of Multiple Forms of Self-regulatory Control in Bulimia Nervosa

Conditions
-----------------
Bulimia Nervosa

Participation Criteria
=================
Eligibility Criteria
-----------------
General Inclusion Criteria: Female Right-handed Between the ages of 18 and 35 years *For Women with Bulimia Nervosa: Binge eating (i.e., eating a large amount of food while experiencing a sense of loss of control) Purging via self-induced vomiting (other methods may also be endorsed) General Exclusion Criteria: Current significant medical illness or condition (e.g., diabetes, thyroid disease) Pregnancy, planned pregnancy, or lactation during the study period Non-removable metallic objects in the body

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Women with Bulimia Nervosa<br> | |
| Women Healthy Controls<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Self-Regulatory Control | Functional Magnetic Resonance Imaging will be used to assess brain activation associated with motor inhibitory control and affect regulation in women with bulimia nervosa (BN) | Day 2 (fMRI Scan) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Goal-Directed Action Control | An computerized instrumental learning task will be used to assess performance of women with and without bulimia nervosa. | Day 1 | 
| Eating Disorder Relevance | The Eating Disorder Examination (EDE) will be conducted to assess relative associations of motor, affective, and goal-directed action control with bulimia nervosa severity. | Day 0 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Bulimia Nervosa, Bulimia, fMRI, Emotion Regulation, Response Inhibition
Ultrasound Guided Obturator Nerve Block for Total Knee Replacement (TKR)

Study Overview
=================
Brief Summary
-----------------
Total Knee Replacement can be performed under the combination of posterior lumbar plexus block plus sciatic nerve block. The investigators can have the same outcome by performing instead of posterior lumbar plexus block more peripheral nerve blocks. More specifically under the combination of sciatic nerve block plus femoral nerve block plus obturator nerve block.

Official Title
-----------------
Comparison of Posterior Lumbar Plexus Block Plus Sciatic Nerve Block With Sciatic Plus Femoral Plus Obturator Nerve Block for Total Knee Replacement (TKR)

Conditions
-----------------
Total Knee Replacement, Surgery

Intervention / Treatment
-----------------
* Other: Sciatic, femoral, obturator nerve blocks
* Other: Sciatic nerve block, posterior lumbar plexus block


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 18 - 80 yrs ASA I - III TKR surgery Exclusion Criteria: Coagulopathy disorders Infection at the puncture site for the interscalene block Neurologic deficit in the arm that is going to be operated Allergy to local anesthetics BMI > 35 Psychiatric disorders Patient's refusal Problems with patient communication

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: TKR, sciatic, femoral, obturator<br>TKR surgery under ultrasound guided sciatic nerve block plus femoral nerve block plus obturator nerve block | Other: Sciatic, femoral, obturator nerve blocks<br> <br> * Other names: Ultrasound guided blocks with ropivacaine;|
| Active Comparator: TKR sciatic nerve block, posterior lumbar plexus block<br>TKR surgery under ultrasound guided sciatic nerve block plus posterior lumbar plexus block | Other: Sciatic nerve block, posterior lumbar plexus block<br> <br> * Other names: Ultrasound guided blocks with ropivacaine;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Feasibility of TKR surgery under ultrasound guided sciatic nerve block plus femoral nerve block plus obturator nerve block measured with Pain Score on the Visual Analog Scale | If the patient complains for pain > 4 in VAS and there is no relief with fentanyl administration the anesthesia plan converts to general anesthesia with laryngeal mask | Completion of surgery | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Intraoperative opioid consumption for TKR surgery under ultrasound guided sciatic nerve block plus femoral nerve block plus obturator nerve block |  | Intaoperatively |
Study of Acute Autoimmune Encephalitis With Positive Antibodies in Eastern France

Study Overview
=================
Brief Summary
-----------------
The number of acute encephalitides diagnosed each year is gradually increasing, reaching approximately 5 to 10/100,000 per year; more than 50% of etiologies currently remain unknown. The majority of them are acute encephalitis of infectious origin, but it is estimated that 20% of encephalitis in northern Europe is related to an autoimmune mechanism with the majority of encephalitis with anti-NMDA Ac discovered recently in 2007. The study of a large American encephalitis cohort showed a death rate of 3% to 7% in cases of autoimmune encephalitis. Furthermore, delay in the initiation of effective treatment (tumor removal or immunotherapy) beyond 4 weeks is associated with a poor prognosis at 1 year. It is therefore necessary to better understand the signs of autoimmune encephalitis in order to recognize the disease quickly and to start a treatment quickly; in order to improve the management and the prognosis of these children.

Official Title
-----------------
Study of Acute Autoimmune Encephalitis With Positive Antibodies in Eastern France Between 2006 and 2018

Conditions
-----------------
Acute Autoimmune Encephalitis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Age between 0 and 17 years at diagnosis Patient diagnosed between 01/01/2006 and 31/12/2018 with autoimmune encephalitis in one of the participating university hospitals (Besançon, Nancy, Strasbourg, Reims and Dijon) Presence of clinical criteria of clinical and/or radiographic encephalitis Presence of one or more antibodies in the blood or CSF Parental authority holders and their child of childbearing age having given their consent for the use of the child's data for this research Exclusion criteria: Refusal to participate in the study Absence of consultation at any of the study centers Absence of clinical and/or radiographic criteria for encephalitis. Absence of antibodies found in blood or CSF

Ages Eligible for Study
-----------------
Minimum Age: 1 Year
Maximum Age: 17 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Retrospective description of autoimmune encephalitis in children |  | Files analysed retrospectively from January 01, 2006 to December 31, 2018 will be examined | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
autoimmune encephalitis, Acute autoimmune encephalitis, encephalitis